One Battle After Another: Broad Institute Wins at PTAB in CRISPR Dispute

Why It Matters

The ruling solidifies Broad’s control over foundational CRISPR patents, shaping licensing terms and R&D incentives across the gene‑editing industry.

Key Takeaways

• Broad Institute declared first to invent eukaryotic CRISPR‑Cas9.
• CVC failed to prove conception of complete CRISPR system.
• PTAB emphasized need for definite, permanent idea under first‑to‑invent.
• Interference proceedings now rare due to AIA first‑to‑file system.
• Ruling strengthens Broad’s licensing position in gene‑editing market.

Pulse Analysis

The Broad Institute’s victory in the PTAB interference marks a pivotal moment in the multi‑year CRISPR patent saga that pits academic innovators against a well‑funded research institute. Under the legacy first‑to‑invent framework, the board scrutinized whether CVC’s documentation captured a complete, operable eukaryotic CRISPR‑Cas9 system at the claimed conception date. By concluding that the evidence fell short of a "definite and permanent" idea, the PTAB reinforced the high evidentiary bar required to claim priority, underscoring how laboratory notebooks and early publications can become liabilities as well as assets.

For the Broad Institute, the decision translates into a stronger bargaining chip in licensing negotiations with biotech firms, academic labs, and therapeutic developers. Control of the core CRISPR‑Cas9 patents enables Broad to set royalty structures and enforce compliance, potentially accelerating commercial adoption while also raising concerns about market concentration. Meanwhile, the University of California and Charpentier’s team must reassess their patent strategy, perhaps focusing on downstream improvements or alternative gene‑editing platforms to retain relevance in a crowded intellectual‑property landscape.

The broader significance lies in the shifting patent paradigm introduced by the America Invents Act. Since 2013, the first‑to‑file system has rendered interference proceedings increasingly obsolete, pushing inventors to file promptly rather than rely on invention dates. This case illustrates the residual risks for legacy applications still caught in the old regime and signals to the biotech sector that robust, timely filing practices are now essential to protect innovation and attract investment.